## RSABE… [Regulatives / Guidelines]

Hi Dear Helmut,

❝ Which book are you referring to?

❝ For the FDA you can apply RSABE for any PK metric (AUCs, partial AUCs, Cmax, ) if its $$\small{s_{\textrm{wR}}\geq 0.294\;(CV_{\textrm{wR}}\geq\approx0.300469\ldots)}$$

❝ If $$\small{s_{\textrm{wR}}<0.294}$$ you have to evaluate the respective PK metric for ABE.

I didn't find this statement in FDA guidance for bioequivalence studies just in progesterone guidance so, is it enough to refer to this guide while submitting the study to regulatory (as the intrasubject variability CV% equal 57%, partially replicate design), or is there another guide would support this way? please advice?